阅读说明：本技术 2-[(3z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸的新用途 (New application of 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylene ] inden-1-yl ] acetic acid ) 是由 米克莱·托姆勒维兹 于 2018-04-11 设计创作，主要内容包括：本发明涉及由式1表示的2-[(3Z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸(舒林酸)的制造用于治疗糖尿病患者不同类型的难以治愈的伤口的药物制剂的新用途。公开了由图1所示式1表示的2-[(3Z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸(舒林酸)的制造用于治疗糖尿病患者不同类型的难以治愈的伤口的药物制剂的医疗用途。一种包含2-[(3Z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸(舒林酸)的药物组合物,其特征在于其以1-200毫克/毫升的量包含由式1表示的2-[(3Z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸。(The present invention relates to a new use of 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylidene ] inden-1-yl ] acetic acid (sulindac) represented by formula 1 for the manufacture of a pharmaceutical preparation for the treatment of different types of intractable wounds in diabetic patients, the medical use of 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylidene ] inden-1-yl ] acetic acid (sulindac) represented by formula 1 shown in fig. 1 for the manufacture of a pharmaceutical preparation for the treatment of different types of intractable wounds in diabetic patients is disclosed a pharmaceutical composition comprising 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylidene ] inden-1-yl ] acetic acid (sulindac), characterized in that it comprises 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylidene ] inden-1-yl ] acetic acid represented by formula 1-200 mg/ml.)

1. Medical use of 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylidene ] inden-1-yl ] acetic acid (sulindac) represented by formula 1 shown in the drawing for the manufacture of a pharmaceutical preparation for the treatment of different types of incurable wounds in diabetic patients.

2. A compound 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylene ] inden-1-yl ] acetic acid represented by formula 1 shown in the drawing, which is used for treating various types of intractable wounds in diabetic patients.

A pharmaceutical composition characterized by comprising 2- [ (3Z) -6-fluoro-2-methyl-3- [ (4-methylsulfinylphenyl) methylene ] inden-1-yl ] acetic acid represented by formula 1 in an amount of 1-200 mg/ml.